12 results about "Cancer cachexia" patented technology

The present invention relates to a composition for the improvement and treatment of muscle diseases and cachexia, wherein diflunisal has the effect of promoting the differentiation and proliferation of myogenic cells, and further has the effect of improving and treating cachexia induced by chronic diseases such as muscle diseases or cancer through effects such as increased muscle mass and recovery of muscle strength.

The present invention relates to a composition for ameliorating or treating cachexia containing calcium lactate as an active ingredient, and a method for treating cancer cachexia in a subject, the method comprising a step of administering calcium lactate or a pharmaceutically acceptable salt or solvate thereof to a subject in need thereof. The calcium lactate of the present invention acts as a Hif-1α inhibitor and exhibits an effect of suppressing body mass loss due to cancer, so that it can be used as a candidate substance for solving the problem of cancer cachexia and suggests a synergistic effect between a medical nutritional product focused on anorexia and malnutrition and a Hif-1α inhibitor.

The present invention relates to the use of an s100a8 / a9 and complement 3 inhibitor in the preparation of a drug for treating or preventing cachexia. The treatment or prevention of cachexia comprises increasing the body weight, lean body mass and fat mass, and increasing food intake in a cachectic subject, or preventing fat mass consumption, slowing the rate of body weight loss, the rate of fat mass loss and the rate of lean body mass loss, counteracting anorexia, muscle strength loss, fatigue and body weight loss, or improving abnormal biochemical results. Provided is a new understanding for the mechanism of energy balance regulation in cancer cachexia, with an emphasis on the effects of S100a8 / a9 and C3 in cancer cachexia. The inhibition of S100a8 / a9 and complement 3 can promote fat recovery and increase food intake. Particularly, it is verified that an S100a8 / a9 inhibitor can prevent body weight loss, especially adipose tissue loss, in a cachectic subject, and significantly increases food intake in the subject.

This invention relates to the use of S100a8 / a9 and complement 3 inhibitors in the preparation of medicaments for the treatment or prevention of cachexia, wherein the treatment or prevention of cachexia involves increasing the body weight, lean body mass, fat mass, and food intake of cachectic subjects, or preventing fat loss, slowing the rate of weight loss, slowing the rate of fat mass loss, slowing the rate of lean body mass loss, resisting anorexia, resisting muscle weakness, resisting fatigue, resisting weight loss, and improving abnormal biochemical results. This invention provides a new understanding of the mechanism of energy balance regulation in cancer cachexia, focusing on the roles of S100a8 / a9 and C3 in cancer cachexia. This invention finds that inhibiting S100a8 / a9 and complement 3 can promote fat recovery and increase food intake. In particular, it demonstrates that S100a8 / a9 inhibitors can prevent the loss of body weight, especially adipose tissue, in cachectic subjects and significantly increase their food intake.

Methods for treating diseases and disorders treatable by AMPK activation with cefin-1 and related compounds, such as metabolic syndrome, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis (NASH), obesity, type 2 diabetes, insulin resistance, glucose intolerance, chronic pain, muscle loss, neuromuscular disorders, heart failure, cardiac hypertrophy, diabetic cardiomyopathy, cardiac reperfusion injury, chronic kidney disease, polycystic kidney disease, diabetic nephropathy, cardiovascular disease, inflammatory bowel disease, arthritis, hypertension, peripheral vascular disease, nephrogenic diabetes insipidus, glaucoma, eye diseases or disorders, ocular angiogenesis, β-hemochromocytic disorder, cancer, fibrosis, cancer cachexia, and mitochondrial diseases.

The application relates to application of a compound in the biological medical field, in particular to application of a benzamide compound in preparation of a drug for preventing and / or treating cancer cachexia. The application of the compound shown in formula I or a pharmaceutically acceptable salt thereof in preparation of a drug for preventing and / or treating cancer cachexia. The compound involved in the application has the effect of significantly improving, reducing and alleviating cancer cachexia, improving the weight of animal body, bone muscle and fat, and has a good application and development prospect.

The invention discloses application of dimethyl fumarate in preparation of a medicine for preventing and / or treating skeletal muscle atrophy, and belongs to the field of medicine. It is proved for the first time that DMF can effectively relieve related symptoms of skeletal muscle atrophy caused by cancer cachexia, and a new thought is provided for treatment of skeletal muscle atrophy. The DMF can relieve skeletal muscle atrophy by reducing mitochondrial damage and improving mitochondrial homeostasis imbalance, and the potential mechanism of the DMF is possibly related to the regulation of HIF1alpha, mTOR and other pathways. In addition, DMF can improve cancer cachexia skeletal muscle atrophy and does not inhibit tumor growth, which indicates that DMF directly acts on skeletal muscle instead of tumor. Due to the common end characteristic of mitochondrial homeostasis imbalance and the like in amyotrophy caused by different causes (such as aging and drug toxicity), the adjusting effect of DMF on homeostasis in skeletal muscle can be expanded to be used for preventing and treating other types of amyotrophy, including amyotrophy caused by aging, glucocorticoid, chemotherapy drugs and the like. The invention provides an application basis for preventing and treating skeletal muscle atrophy by DMF.

The present invention relates to a novel use of a CXCL5 inhibitor and a novel antibody or antigen-binding fragment thereof usable as a CXCL5 inhibitor. The novel use of a CXCL5 inhibitor and the novel antibody or antigen-binding fragment thereof usable as a CXCL5 inhibitor of the present invention enable the treatment or prevention of cancer cachexia or muscle disease, enable cancer cachexia or muscle disease to be diagnosed with high efficiency, and enable a drug for the treatment or prevention of cancer cachexia or muscle disease to be screened with high efficiency.

The application relates to the technical field of medical systems, and particularly discloses a construction method of a cancer cachexia prognosis composite index CCAR based on a combination of creatinine and CAR, which comprises the following steps: S1, obtaining serum biomarker data of a cancer cachexia patient, including creatinine, C-reactive protein and albumin; S2, calculating a C-reactive protein to albumin ratio CAR=CRP / Albumin; S3, taking CAR and Cr as input features, and constructing a nonlinear composite index CCAR through a random forest machine learning model; and S4, developing a network calculator system; the CCAR index constructed by the application can comprehensively reflect the inflammatory burden, metabolic state and immune level of a cancer cachexia patient, can provide more accurate survival prognosis prediction compared with traditional indexes, and the parameters, such as creatinine, C-reactive protein to albumin ratio, contained in the CCAR index are all common blood examination items in clinical practice, so that the CCAR index is convenient to obtain and can be widely applied in clinical practice.

The invention features polypeptides that include an extracellular ActRIIa variant. In some embodiments, a polypeptide of the invention includes an extracellular ActRIIa variant fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving weakness and atrophy of muscles, e.g., Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, inclusion body myositis, amyotrophic lateral sclerosis, sarcopenia; or cancer cachexia; or metabolic diseases, e.g., obesity, Type-1 diabetes, or Type-2 diabetes.

The invention relates to an application of an indoleamine 2, 3-dioxygenase 1 inhibitor in preparation of a medicine for treating cancer cachexia. The indoleamine 2, 3-dioxygenase 1 is determined as a core therapeutic target of cancer cachexia for the first time, and it is proved that palmatine hydrochloride shows an exact therapeutic effect in cell and animal models through a multi-channel synergistic mechanism of metabolic reprogramming, protein degradation inhibition, anabolism signal recovery and muscle regeneration promotion. And sufficient experimental basis and theoretical support are provided for clinical transformation.